255 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
15 Feb 24
Results of Operations and Financial Condition
8:10am
candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare … ” strategy, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare … ” strategy should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward
8-K
EX-99.1
60cz g6ykkkbv5epjf6
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
mmb25k5trxh9grv
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
EX-99.1
bf6sla2ty8k4f
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
kokvrek
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
3flocbi
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
EX-99.1
28cbfdmi
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
0wij5teasz2mfdcn
27 Oct 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.2
s8j9f qr89xbhu
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm
8-K
EX-99.1
v4q g07nlq2
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm